DK2904111T3 - Immunkompetence evaluering af adaptiv immunreceptor diversitet og klonalitet karakterisering - Google Patents
Immunkompetence evaluering af adaptiv immunreceptor diversitet og klonalitet karakterisering Download PDFInfo
- Publication number
- DK2904111T3 DK2904111T3 DK13779666.0T DK13779666T DK2904111T3 DK 2904111 T3 DK2904111 T3 DK 2904111T3 DK 13779666 T DK13779666 T DK 13779666T DK 2904111 T3 DK2904111 T3 DK 2904111T3
- Authority
- DK
- Denmark
- Prior art keywords
- air
- immunotherapy
- polypeptide
- tcr
- sequences
- Prior art date
Links
- 230000003044 adaptive effect Effects 0.000 title claims description 51
- 108091008915 immune receptors Proteins 0.000 title claims description 35
- 102000027596 immune receptors Human genes 0.000 title claims description 33
- 238000012512 characterization method Methods 0.000 title description 7
- 238000011156 evaluation Methods 0.000 title description 2
- 108091008874 T cell receptors Proteins 0.000 claims abstract description 258
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims abstract description 249
- 238000000034 method Methods 0.000 claims abstract description 153
- 238000009169 immunotherapy Methods 0.000 claims abstract description 152
- 238000009826 distribution Methods 0.000 claims abstract description 92
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 84
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 78
- 229920001184 polypeptide Polymers 0.000 claims abstract description 77
- 238000012360 testing method Methods 0.000 claims description 112
- 206010028980 Neoplasm Diseases 0.000 claims description 97
- 238000011282 treatment Methods 0.000 claims description 66
- 108020004414 DNA Proteins 0.000 claims description 63
- 150000007523 nucleic acids Chemical group 0.000 claims description 62
- 230000004044 response Effects 0.000 claims description 57
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 51
- 210000004027 cell Anatomy 0.000 claims description 49
- 230000028993 immune response Effects 0.000 claims description 40
- 238000012163 sequencing technique Methods 0.000 claims description 33
- 239000003155 DNA primer Substances 0.000 claims description 26
- 239000003112 inhibitor Substances 0.000 claims description 25
- 210000004698 lymphocyte Anatomy 0.000 claims description 25
- 241000282414 Homo sapiens Species 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 238000007403 mPCR Methods 0.000 claims description 21
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 16
- 102000017578 LAG3 Human genes 0.000 claims description 15
- 201000001441 melanoma Diseases 0.000 claims description 14
- 102000005962 receptors Human genes 0.000 claims description 14
- 108020003175 receptors Proteins 0.000 claims description 14
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 12
- 238000003556 assay Methods 0.000 claims description 12
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 229960005386 ipilimumab Drugs 0.000 claims description 11
- 230000003211 malignant effect Effects 0.000 claims description 11
- 101150013553 CD40 gene Proteins 0.000 claims description 10
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 10
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 10
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 8
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 8
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 8
- 241000894007 species Species 0.000 claims description 8
- 229960005486 vaccine Drugs 0.000 claims description 8
- 210000000987 immune system Anatomy 0.000 claims description 7
- 230000001024 immunotherapeutic effect Effects 0.000 claims description 7
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 6
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 6
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 239000003018 immunosuppressive agent Substances 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 5
- 239000002299 complementary DNA Substances 0.000 claims description 5
- 238000011002 quantification Methods 0.000 claims description 5
- 229950007217 tremelimumab Drugs 0.000 claims description 5
- 238000013213 extrapolation Methods 0.000 claims description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 4
- 238000013178 mathematical model Methods 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 3
- 239000003623 enhancer Substances 0.000 claims description 3
- 201000005787 hematologic cancer Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 241000282465 Canis Species 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 241000283984 Rodentia Species 0.000 claims description 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 117
- 230000001900 immune effect Effects 0.000 abstract description 46
- 210000005006 adaptive immune system Anatomy 0.000 abstract description 31
- 210000003719 b-lymphocyte Anatomy 0.000 abstract description 30
- 108060003951 Immunoglobulin Proteins 0.000 abstract description 16
- 102000018358 immunoglobulin Human genes 0.000 abstract description 16
- 239000013615 primer Substances 0.000 description 140
- 239000000523 sample Substances 0.000 description 123
- 210000004369 blood Anatomy 0.000 description 73
- 239000008280 blood Substances 0.000 description 73
- 108090000623 proteins and genes Proteins 0.000 description 68
- 125000003729 nucleotide group Chemical group 0.000 description 56
- 239000002773 nucleotide Substances 0.000 description 55
- 210000004700 fetal blood Anatomy 0.000 description 45
- 208000015181 infectious disease Diseases 0.000 description 37
- 238000002054 transplantation Methods 0.000 description 34
- 210000001519 tissue Anatomy 0.000 description 30
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 28
- 230000008707 rearrangement Effects 0.000 description 28
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 24
- 108091034117 Oligonucleotide Proteins 0.000 description 24
- 201000011510 cancer Diseases 0.000 description 22
- 230000001965 increasing effect Effects 0.000 description 20
- 238000005259 measurement Methods 0.000 description 19
- 230000003321 amplification Effects 0.000 description 18
- 230000000295 complement effect Effects 0.000 description 18
- 238000003199 nucleic acid amplification method Methods 0.000 description 18
- 208000009329 Graft vs Host Disease Diseases 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 17
- 201000010099 disease Diseases 0.000 description 17
- 208000024908 graft versus host disease Diseases 0.000 description 17
- 238000003752 polymerase chain reaction Methods 0.000 description 17
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 238000011084 recovery Methods 0.000 description 16
- 102000053602 DNA Human genes 0.000 description 15
- 230000008595 infiltration Effects 0.000 description 15
- 238000001764 infiltration Methods 0.000 description 15
- 230000001052 transient effect Effects 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 238000009396 hybridization Methods 0.000 description 14
- 210000000130 stem cell Anatomy 0.000 description 14
- 210000001185 bone marrow Anatomy 0.000 description 13
- 210000002865 immune cell Anatomy 0.000 description 13
- 102000040430 polynucleotide Human genes 0.000 description 13
- 108091033319 polynucleotide Proteins 0.000 description 13
- 239000002157 polynucleotide Substances 0.000 description 13
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 12
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 12
- 238000004422 calculation algorithm Methods 0.000 description 12
- 238000003776 cleavage reaction Methods 0.000 description 12
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 12
- 230000007017 scission Effects 0.000 description 12
- 102000013816 Cytotoxic T-lymphocyte antigen 4 Human genes 0.000 description 11
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 11
- 230000002458 infectious effect Effects 0.000 description 11
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 11
- 230000001400 myeloablative effect Effects 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 230000002441 reversible effect Effects 0.000 description 11
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 10
- 238000001574 biopsy Methods 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000037361 pathway Effects 0.000 description 10
- 230000006798 recombination Effects 0.000 description 10
- 238000005215 recombination Methods 0.000 description 10
- 101150008942 J gene Proteins 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 238000012165 high-throughput sequencing Methods 0.000 description 9
- 230000000977 initiatory effect Effects 0.000 description 9
- 230000000670 limiting effect Effects 0.000 description 9
- 230000002085 persistent effect Effects 0.000 description 9
- 238000011870 unpaired t-test Methods 0.000 description 9
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 8
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 8
- 101150117115 V gene Proteins 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 210000001671 embryonic stem cell Anatomy 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000010369 molecular cloning Methods 0.000 description 8
- 244000052769 pathogen Species 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 101150030213 Lag3 gene Proteins 0.000 description 7
- 230000000735 allogeneic effect Effects 0.000 description 7
- 238000000137 annealing Methods 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 239000012472 biological sample Substances 0.000 description 7
- 238000004364 calculation method Methods 0.000 description 7
- 230000001010 compromised effect Effects 0.000 description 7
- 230000003750 conditioning effect Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 230000009258 tissue cross reactivity Effects 0.000 description 7
- 208000023275 Autoimmune disease Diseases 0.000 description 6
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 6
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 6
- 238000000585 Mann–Whitney U test Methods 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 6
- 230000005867 T cell response Effects 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000002596 correlated effect Effects 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 238000002650 immunosuppressive therapy Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 5
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 5
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 description 5
- 206010071578 autoimmune retinopathy Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000004968 inflammatory condition Effects 0.000 description 5
- 238000005304 joining Methods 0.000 description 5
- 208000021039 metastatic melanoma Diseases 0.000 description 5
- -1 nucleoside triphosphates Chemical class 0.000 description 5
- 238000009258 post-therapy Methods 0.000 description 5
- 238000002203 pretreatment Methods 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 108010074708 B7-H1 Antigen Proteins 0.000 description 4
- 101150097493 D gene Proteins 0.000 description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 102000004890 Interleukin-8 Human genes 0.000 description 4
- 108090001007 Interleukin-8 Proteins 0.000 description 4
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 4
- 108091081021 Sense strand Proteins 0.000 description 4
- 230000006044 T cell activation Effects 0.000 description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 4
- 241000287433 Turdus Species 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 208000024340 acute graft versus host disease Diseases 0.000 description 4
- 230000033289 adaptive immune response Effects 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 239000013060 biological fluid Substances 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229960000390 fludarabine Drugs 0.000 description 4
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- 229940125721 immunosuppressive agent Drugs 0.000 description 4
- 229940100601 interleukin-6 Drugs 0.000 description 4
- 229940096397 interleukin-8 Drugs 0.000 description 4
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 4
- 230000002601 intratumoral effect Effects 0.000 description 4
- 210000002751 lymph Anatomy 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 230000000392 somatic effect Effects 0.000 description 4
- 238000011269 treatment regimen Methods 0.000 description 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 4
- 108091093088 Amplicon Proteins 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 230000006820 DNA synthesis Effects 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 3
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 3
- 101710203526 Integrase Proteins 0.000 description 3
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 3
- 241000764238 Isis Species 0.000 description 3
- 102100033467 L-selectin Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229910003460 diamond Inorganic materials 0.000 description 3
- 239000010432 diamond Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 238000007876 drug discovery Methods 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000007899 nucleic acid hybridization Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 3
- 229960004618 prednisone Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 3
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 2
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 108091008048 CMVpp65 Proteins 0.000 description 2
- 206010068051 Chimerism Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101000759926 Homo sapiens Ubiquitin carboxyl-terminal hydrolase isozyme L1 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 2
- 239000012270 PD-1 inhibitor Substances 0.000 description 2
- 239000012668 PD-1-inhibitor Substances 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 2
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 2
- 241000906446 Theraps Species 0.000 description 2
- YCPOZVAOBBQLRI-WDSKDSINSA-N Treosulfan Chemical compound CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-WDSKDSINSA-N 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 102100025038 Ubiquitin carboxyl-terminal hydrolase isozyme L1 Human genes 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 229960002964 adalimumab Drugs 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 108091036078 conserved sequence Proteins 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 229960000403 etanercept Drugs 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 210000001822 immobilized cell Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229960000598 infliximab Drugs 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000000207 lymphocyte subset Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000003519 mature b lymphocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000002625 monoclonal antibody therapy Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 2
- 229960004866 mycophenolate mofetil Drugs 0.000 description 2
- 210000001178 neural stem cell Anatomy 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 229940121655 pd-1 inhibitor Drugs 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000011853 postimmunotherapy Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 229960003181 treosulfan Drugs 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 240000002022 Anthriscus cerefolium Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000867610 Chlorocebus pygerythrus Species 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 201000003874 Common Variable Immunodeficiency Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 101000611185 Homo sapiens Tumor necrosis factor receptor superfamily member 5 Proteins 0.000 description 1
- 108700029227 Immunoglobulin Light Chain Genes Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 239000006091 Macor Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 208000017414 Precursor T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 108091008109 Pseudogenes Proteins 0.000 description 1
- 102000057361 Pseudogenes Human genes 0.000 description 1
- 101100396930 Pseudomonas aeruginosa imm1 gene Proteins 0.000 description 1
- 102000001183 RAG-1 Human genes 0.000 description 1
- 108060006897 RAG1 Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 101150002618 TCRP gene Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 108010032099 V(D)J recombination activating protein 2 Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- SWPYNTWPIAZGLT-UHFFFAOYSA-N [amino(ethoxy)phosphanyl]oxyethane Chemical compound CCOP(N)OCC SWPYNTWPIAZGLT-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006786 activation induced cell death Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 1
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 229950007409 dacetuzumab Drugs 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000012953 feeding on blood of other organism Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 230000012178 germinal center formation Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000009033 hematopoietic malignancy Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000008938 immune dysregulation Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000008102 immune modulation Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 229940124622 immune-modulator drug Drugs 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 210000000428 immunological synapse Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000037456 inflammatory mechanism Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229950004563 lucatumumab Drugs 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000017869 myelodysplastic/myeloproliferative disease Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 1
- 238000007474 nonparametric Mann- Whitney U test Methods 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000004912 pericardial fluid Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000004911 serous fluid Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (13)
1. Fremgangsmåde til at forudsige et immunologisk respons hos et forsøgsindivid af en immunterapi omfattende: at amplificere nukleinsyresekvenser fra en eller flere faste tumorprøver, der omfatter lymfoide celler, hvori prøverne er tilvejebragt fra forsøgsindividet ved et eller flere tidspunkter forud for og efter behandling med nævnte immunterapi, og hvor nukleinsyresekvenserne er amplificeret i et multipleks PCR-assay ved anvendelse af et stort antal adaptive immunreceptor (AIR) V-segment oligonukleotidprimere og enten et stort antal AIR J-segment oligonukleotidprimere eller et eller flere AIR C-segment oligonukleotidprimere; at tilvejebringe nukleinsyresekvensinformation fra de amplificerede nukleinsyresekvenser, hvori nævnte nukleinsyresekvensinformationen omfatter sekvenser for et stort antal unikke omarrangerede nukleinsyresekvenser, der hver koder for et adaptivt immunreceptor (AIR) polypeptid; at kvantificere en AIR sekvensdiversitetsscore for nævnte ene eller flere faste tumorprøver baseret på det samlede antal unikke omarrangerede DNA-sekvenser i nævnte ene eller flere faste tumorprøver, hvor nævnte AIR sekvensdiversitetsscore kvantificeres under anvendelse af nukleinsyresekvensinformationen ; at kvantificere en AIR sekvensfordelingsscore for nævnte ene eller flere faste tumorprøver ved at beregne en hyppighed af forekomsten af et stort antal unikke omarrangerede DNA-sekvenser i nævnte ene eller flere faste tumorprøver, hvor nævnte AIR sekvensfordelingsscore kvantificeres under anvendelse af nævnte nukleinsyresekvensinformation; at bestemme en forsøgsindividvurderingsscore for nævnte ene eller flere faste tumorprøver baseret på nævnte AIR sekvensdiversitetsscore og nævnte AIR sekvensfordelingsscore; at sammenligne nævnte forsøgsindividvurderingsscore med en kontrolemnevurderingsscore, der er opnået fra en prøve fra et kontroleme med et kendt respons på nævnte immunterapi; og at forudsige et immunologisk respons for nævnte forsøgsindivid for nævnte immunterapi baseret på nævnte sammenligning.
2. Fremgangsmåde ifølge krav 1, hvor nævnte nukleinsyrer omfatter genomisk DNA, cDNA eller mRNA.
3. Fremgangsmåde ifølge krav 1 eller krav 2, hvor bestemmelse af en forsøgsindividvurderingsscore omfatter at kvantificere en AIR sekvensfordelingsscore for nævnte forsøgsindivid ved: at bestemme et antal unikke omarrangerede AIR sekvenser, der tegner sig for en kombineret hyppighed af forekomsten på op til 50%, 40%, 30%, 20% eller 10% af det samlede antal observerede omarrangerede sekvenser i nævnte prøve; og at karakterisere nævnte AIR sekvensfordelingsscore som en lav score, hvis antallet af unikke omarrangerede AIR sekvenser, der har nævnte kombinerede hyppighed af forekomsten af det samlede antal observerede omarrangerede sekvenser i nævnte prøve, er mindre end eller lig med en forudbestemt tærskelværdi.
4. Fremgangsmåde ifølge krav 1, hvor nævnte forsøgsindivid (i) forudsiges at have det samme responsresultat af immunterapi sammenlignet med kontrolemnet eller (ii) forudsiges at have et andet responsresultat af immunterapi sammenlignet med nævnte kontrolemne.
5. Fremgangsmåde ifølge krav 1, hvor nævnte immunterapi omfatter: (i) et immunterapeutisk antistof, et cytokin, et immunsuppressivt middel eller en vaccine; (ii) en inhibitor af en negativ regulator af immunsystemet, valgfrit hvori enten (a) nævnte negative regulator er valgt fra en gruppe bestående af CTLA-4, LAG3 og PD-1 eller (b) nævnte inhibitor er et anti-PD-1 antistof eller et anti-CTLA-4 antistof valgt fra gruppen bestående af ipilimumab og tremelimumab; eller (iii) et middel, rettet mod en immunresponsforstærker, valgfrit hvori nævnte immunresponsforstærker er valgt blandt 41BB/CD137, OX40/CD134 og CD40.
6. Fremgangsmåde ifølge krav 1, der yderligere omfatter at bestemme en tilstedeværelse af en klonekspansion af mindst en klon i en prøve, der er tilvejebragt fra nævnte forsøgsindivid efter nævnte immunterapibehandling, hvori nævnte mindst ene klon har en hyppighed af forekomst, der er statistisk signifikant forskellig fra en gennemsnitlig hyppighed af forekomst af et sæt resterende kloner i nævnte prøve og tidligere ikke havde en hyppighed af forekomst, som var statistisk signifikant forskellig fra en gennemsnitlig hyppighed af forekomst af et sæt resterende kloner i en prøve tilvejebragt fra nævnte forsøgsindivid forud for nævnte immunterapi.
7. Fremgangsmåde ifølge krav 6, hvor nævnte sæt af resterende kloner omfatter kloner, som hver har en hyppighed af forekomst, der er i top 50%, 40%, 30%, 20% eller 10% af de samlede kloner i prøven.
8. Fremgangsmåde ifølge krav 6, hvor nævnte klonekspansion af nævnte mindst ene klon er indicerende for et dårlig respons af nævnte forsøgsindivid for nævnte immunterapibehandling.
9. Fremgangsmåde ifølge krav 1, hvor bestemmelse af en forsøgsindividvurderingsscore omfatter bestemmelse af en AIR sekvensfordelingsscore for nævnte ene eller flere prøver ved at vælge et sæt af unikke omarrangerede sekvenser i en af nævnte prøver med en hyppighed af forekomst, der er statistisk signifikant højere sammenlignet med en tærskelhyppighed af forekomsten, der er fastsat af andre unikke omarrangerede sekvenser i nævnte ene eller flere prøver.
10. Fremgangsmåde ifølge krav 1, der yderligere omfatter: at kategorisere nævnte forsøgsindivid baseret på nævnte forsøgsindividvurderingsscore i nævnte ene eller flere prøver som en ikke-responder eller responder til immunterapi i sammenligning med kontrolemnet og at stratificere en patientpopulation af forsøgsindivider ifølge den relative sandsynlighed for at reagere på immunterapi.
11. Fremgangsmåde ifølge krav 1, hvor: (i) at bestemme nævnte forsøgsindividvurderingsscore omfatter ekstrapolering baseret på en matematisk model af en samlet AIR repertoire diversitet af nævnte forsøgsindivid ved sekventering af nukleinsyresekvenserne fra en af nævnte prøver og bestemmelse af et forsøgsindividvurderingsscore fra nævnte samlede AIR repertoire diversitet, optimalt hvor nævnte matematiske model er en uset artsmodel; eller (i i) at bestemme den nævnte forsøgsindividvurderingsscore hvilket omfatter kvantificering af en AIR sekvensfordelingsscore, hvor nævnte kvantificering af nævnte AIR fordelingsscore omfatter at beregne en Shannon entropiscore ved anvendelse af nævnte nukleinsyresekvensinformation fra nævnte ene eller flere prøver.
12. Fremgangsmåde ifølge krav 1, hvor nævnte adaptive immunreceptor (AIR) polypeptid er et pattedyr AIR polypeptid og er valgt fra et T-celle receptor-gamma (TCRG) polypeptid, et T-celle receptor-beta (TCRB) polypeptid, en T-celle receptor alpha (TCRA) polypeptid, et T-celle receptor-delta (TCRD) polypeptid, et immunoglobulin tungkædet (IGH) polypeptid og et immunoglobulin letkædet (IGL) polypeptid, eventuelt hvori: (i) nævnte IGH polypeptid er valgt fra et IgM, et IgA polypeptid, et IgG polypeptid, et IgD polypeptid og et IgE polypeptid; (ii) nævnte IGL polypeptid er valgt fra et IGL-lambda polypeptid og et IGL-kappa polypeptid; eller (iii) nævnte pattedyr AIR polypeptid er valgt fra et humant AIR polypeptid, et ikke-humant primat AIR polypeptid, et gnaver AIR polypeptid, et hunde AIR polypeptid, et katte AIR polypeptid og et ungulat AIR polypeptid.
13. Fremgangsmåde ifølge krav 1, hvor nævnte forsøgsindivid er et individ, der har eller mistænkes for at have en ondartet lidelse, eventuelt hvor: (i) den ondartede lidelse er valgt blandt en hæmatologisk malignitet, et melanom, en sarcom og et carcinom; eller (ii) den ondartede lidelse er valgt blandt ondartet melanom, småcellet lungekræft, ikke-småcellet lungekræft, nyrecellekarcinom, bugspytkirtelcancer, brystkræft, ovariecancer og prostatacancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261708534P | 2012-10-01 | 2012-10-01 | |
| PCT/US2013/062925 WO2014055561A1 (en) | 2012-10-01 | 2013-10-01 | Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2904111T3 true DK2904111T3 (da) | 2018-03-12 |
Family
ID=49447810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13779666.0T DK2904111T3 (da) | 2012-10-01 | 2013-10-01 | Immunkompetence evaluering af adaptiv immunreceptor diversitet og klonalitet karakterisering |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US20160002731A1 (da) |
| EP (3) | EP3330384B1 (da) |
| JP (1) | JP6449160B2 (da) |
| CN (1) | CN105189779B (da) |
| AU (2) | AU2013327423B2 (da) |
| CA (1) | CA2886647A1 (da) |
| DK (1) | DK2904111T3 (da) |
| ES (2) | ES2660027T3 (da) |
| IL (1) | IL238093B (da) |
| WO (1) | WO2014055561A1 (da) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2556171T1 (sl) | 2010-04-05 | 2016-03-31 | Prognosys Biosciences, Inc. | Prostorsko kodirane biološke analize |
| US20190300945A1 (en) | 2010-04-05 | 2019-10-03 | Prognosys Biosciences, Inc. | Spatially Encoded Biological Assays |
| US10787701B2 (en) | 2010-04-05 | 2020-09-29 | Prognosys Biosciences, Inc. | Spatially encoded biological assays |
| GB201106254D0 (en) | 2011-04-13 | 2011-05-25 | Frisen Jonas | Method and product |
| JP6449160B2 (ja) | 2012-10-01 | 2019-01-09 | アダプティブ バイオテクノロジーズ コーポレイション | 適応免疫受容体多様性およびクローン性特性決定による免疫能力評価関連出願の相互参照 |
| EP4592400A3 (en) | 2012-10-17 | 2025-10-29 | 10x Genomics Sweden AB | Methods and product for optimising localised or spatial detection of gene expression in a tissue sample |
| EP4219745B1 (en) | 2013-06-25 | 2025-09-03 | Prognosys Biosciences, Inc. | Spatially encoded biological assays using a microfluidic device |
| CN106103711A (zh) | 2013-11-21 | 2016-11-09 | 组库创世纪株式会社 | T细胞受体和b细胞受体库分析系统及其在治疗和诊断中的应用 |
| EP3092318A4 (en) * | 2014-01-10 | 2017-08-16 | Adaptive Biotechnologies Corp. | Methods for defining and predicting immune response to allograft |
| EP2937698A1 (en) * | 2014-04-25 | 2015-10-28 | ImmunID | Use of immune combinatorial diversity as a predictive marker for identifying patients likely to respond to an anti-CTLA-4 treatment |
| WO2015162596A1 (en) | 2014-04-25 | 2015-10-29 | Immunid | Use of immune diversity as a predictive marker for identifying patients likely to respond to an anti-ctla4 treatment |
| US10092645B2 (en) * | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| EP2975137A1 (en) * | 2014-07-18 | 2016-01-20 | ImmunID | Use of immune diversity as a predictive marker for identifying B-cell-lymphomas-patients having an increased risk of febrile or infectious event |
| EP3715455A1 (en) | 2014-10-29 | 2020-09-30 | Adaptive Biotechnologies Corp. | Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples |
| CA2968543C (en) | 2014-11-25 | 2024-04-02 | Adaptive Biotechnologies Corporation | Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing |
| CN107667178A (zh) * | 2015-03-26 | 2018-02-06 | 休斯敦大学系统 | 细胞的整合功能和分子概况 |
| DK3901281T4 (da) | 2015-04-10 | 2025-10-20 | Illumina Inc | Rumligt adskilt, multipleks nukleinsyreanalyse af biologiske prøver |
| US10539564B2 (en) | 2015-07-22 | 2020-01-21 | Roche Sequencing Solutions, Inc. | Identification of antigen epitopes and immune sequences recognizing the antigens |
| WO2017013170A1 (en) | 2015-07-22 | 2017-01-26 | F. Hoffmann-La Roche Ag | Identification of antigen epitopes and immune sequences recognizing the antigens |
| GB201516047D0 (en) | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
| WO2017165614A1 (en) * | 2016-03-23 | 2017-09-28 | The Methodist Hospital System | Pre-transplant tcr clonality assessment to predict post-liver transplant survival |
| US20170298440A1 (en) * | 2016-04-18 | 2017-10-19 | The Regents Of The University Of California | Materials and methods for improving the effectiveness of immunomodulatory cancer therapy and related methodologies |
| EP3516078B1 (en) * | 2016-09-23 | 2024-12-04 | Life Technologies Corporation | Compositions and methods for assessing immune response |
| EP3521425A4 (en) * | 2016-09-29 | 2019-10-23 | FUJIFILM Corporation | PROCESS FOR DESIGNING PRIMERS FOR MULTIPLEX PCR |
| EP3571320B1 (en) | 2017-01-17 | 2022-04-06 | Life Technologies Corporation | Compositions and methods for immune repertoire sequencing |
| US11858994B2 (en) | 2017-03-15 | 2024-01-02 | Repertoire Genesis Incorporation | Biomarkers for cancer immunotherapy |
| CN106987631A (zh) * | 2017-04-01 | 2017-07-28 | 武汉赛云博生物科技有限公司 | 一种用于pd‑1/pd‑l1阻断治疗伴随诊断的免疫组测序技术 |
| JP6990522B2 (ja) | 2017-04-11 | 2022-02-03 | シスメックス株式会社 | 免疫細胞の免疫刺激応答性を測定する方法、免疫細胞における免疫シナプスの形成能を判定する方法及び細胞分析装置 |
| US11754552B2 (en) * | 2017-06-09 | 2023-09-12 | The Regents Of The University Of California | Use of immune repertoire diversity for predicting transplant rejection |
| CN111164700B (zh) * | 2017-07-14 | 2024-10-29 | 余因子基因组学公司 | 使用下一代测序的免疫-肿瘤学应用 |
| WO2019046817A1 (en) * | 2017-09-01 | 2019-03-07 | Life Technologies Corporation | COMPOSITIONS AND METHODS FOR IMMUNOLOGICAL REPERTOIRE SEQUENCING |
| CN111465990B (zh) * | 2017-10-06 | 2023-09-12 | 皇家飞利浦有限公司 | 用于医疗保健临床试验的方法和系统 |
| WO2019079762A1 (en) * | 2017-10-20 | 2019-04-25 | Children's National Medical Center | METHODS OF DISCOVERING ANTIBODIES USING TRANSCRIPTOMES AND COMPOSITIONS DERIVED THEREFROM |
| WO2019183582A1 (en) * | 2018-03-23 | 2019-09-26 | Life Technologies Corporation | Immune repertoire monitoring |
| US20210217495A1 (en) * | 2018-07-02 | 2021-07-15 | Beth Israel Deaconess Medical Center, Inc. | Method For Machine Learning To Find Patterns In Ensembles Of Biological Sequences Based On Biophysical Properties |
| US12473663B2 (en) | 2018-07-18 | 2025-11-18 | Life Technologies Corporation | Compositions and methods for immune repertoiresequencing |
| CN109002689B (zh) * | 2018-07-23 | 2020-10-09 | 西安交通大学医学院第一附属医院 | T细胞数据处理方法及装置 |
| WO2020198299A1 (en) * | 2019-03-26 | 2020-10-01 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for characterizing and treating alzheimer's disease |
| AU2020256218A1 (en) * | 2019-04-05 | 2021-01-21 | Illumina, Inc. | Quantitative score of HLA diversity |
| WO2020236850A1 (en) * | 2019-05-20 | 2020-11-26 | Immunovalent Therapeutics Inc. | Solid phase devices and methods of use for purifying and quantifying tissue-specific leukocytes |
| WO2020243579A1 (en) | 2019-05-30 | 2020-12-03 | 10X Genomics, Inc. | Methods of detecting spatial heterogeneity of a biological sample |
| WO2020247263A1 (en) * | 2019-06-06 | 2020-12-10 | Natera, Inc. | Methods for detecting immune cell dna and monitoring immune system |
| US12263179B1 (en) | 2019-08-01 | 2025-04-01 | Adaptive Biotechnologies Corporation | Lyme disease-associated T cell receptor-related methods |
| AU2021283174A1 (en) | 2020-06-02 | 2023-01-05 | 10X Genomics, Inc. | Nucleic acid library methods |
| EP4600376A3 (en) | 2020-06-02 | 2025-10-22 | 10X Genomics, Inc. | Spatial transcriptomics for antigen-receptors |
| WO2021252499A1 (en) | 2020-06-08 | 2021-12-16 | 10X Genomics, Inc. | Methods of determining a surgical margin and methods of use thereof |
| US12266425B1 (en) | 2020-06-10 | 2025-04-01 | Adaptive Biotechnologies Corporation | T cell receptor sequences diagnostic for COVID-19 and related compositions |
| CN112280858B (zh) * | 2020-10-26 | 2022-11-01 | 中国医学科学院肿瘤医院 | Tcr多样性的测定方法和应用 |
| CN112331344B (zh) * | 2020-11-12 | 2021-08-03 | 深圳泛因医学有限公司 | 免疫状态评估方法及应用 |
| AU2022245323A1 (en) | 2021-03-24 | 2023-09-28 | Genentech, Inc. | Efficient tcr gene editing in t lymphocytes |
| WO2023201265A1 (en) * | 2022-04-12 | 2023-10-19 | The Johns Hopkins University | Method of measuring level of immune suppression |
| WO2024073682A2 (en) * | 2022-09-30 | 2024-04-04 | Memorial Sloan-Kettering Cancer Center | Methods to measure antigen-specific t cell clones and uses thereof |
| WO2025096938A1 (en) * | 2023-11-01 | 2025-05-08 | Dana-Farber Cancer Institute, Inc. | Methods of predicting relapse post hematopoietic stem-cell transplantation and methods of treatment |
Family Cites Families (335)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3270960A (en) | 1964-09-11 | 1966-09-06 | Sperry Rand Corp | Fluid sensor |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| DE3211263A1 (de) | 1981-03-31 | 1983-01-27 | Otsuka Pharmaceutical Co. Ltd., Tokyo | Human-interferon verwandte peptide, antigene und antikoerper, sowie verfahren zu deren herstellung |
| DE3238353A1 (de) | 1982-10-15 | 1984-04-19 | Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | Verfahren zur simultanen quantitativen bestimmung der blutzellen und reagenz hierfuer |
| US5189147A (en) | 1984-06-13 | 1993-02-23 | Massachusetts Institute Of Technology | Meterodimeric T lymphocyte receptor antibody |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| DE3541033A1 (de) | 1985-11-19 | 1987-05-21 | Boehringer Mannheim Gmbh | Verfahren zur quantifizierung von zellpopulationen bzw. subpopulationen sowie hierfuer geeignetes reagenz |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US4942124A (en) | 1987-08-11 | 1990-07-17 | President And Fellows Of Harvard College | Multiplex sequencing |
| US5149625A (en) | 1987-08-11 | 1992-09-22 | President And Fellows Of Harvard College | Multiplex analysis of DNA |
| US5667967A (en) | 1990-05-01 | 1997-09-16 | The Board Of Trustees Of The Leland Stanford Junior University | T-cell receptor varible transcripts as disease related markers |
| US6031091A (en) | 1987-09-21 | 2000-02-29 | Gen-Probe Incorporated | Non-nucleotide linking reagents for nucleotide probes |
| US5506126A (en) | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
| US5168038A (en) | 1988-06-17 | 1992-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | In situ transcription in cells and tissues |
| WO1990004648A1 (en) | 1988-10-20 | 1990-05-03 | Alexander Alan Morley | Method for diagnosis of monoclonality in leukaemia and lymphoma |
| US5075217A (en) | 1989-04-21 | 1991-12-24 | Marshfield Clinic | Length polymorphisms in (dC-dA)n ·(dG-dT)n sequences |
| US5231012A (en) | 1989-06-28 | 1993-07-27 | Schering Corporation | Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10) |
| CA2020958C (en) | 1989-07-11 | 2005-01-11 | Daniel L. Kacian | Nucleic acid sequence amplification methods |
| US5336598A (en) | 1989-11-15 | 1994-08-09 | National Jewish Center For Immunology And Respiratory Medicine | Method for diagnosing a superantigen caused pathologial condition via assay of T-cells |
| US5298396A (en) | 1989-11-15 | 1994-03-29 | National Jewish Center For Immunology And Respiratory Medicine | Method for identifying T cells disease involved in autoimmune disease |
| US6054034A (en) | 1990-02-28 | 2000-04-25 | Aclara Biosciences, Inc. | Acrylic microchannels and their use in electrophoretic applications |
| US5126022A (en) | 1990-02-28 | 1992-06-30 | Soane Tecnologies, Inc. | Method and device for moving molecules by the application of a plurality of electrical fields |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6916605B1 (en) | 1990-07-10 | 2005-07-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| IE76732B1 (en) | 1990-08-07 | 1997-11-05 | Becton Dickinson Co | One step test for absolute counts |
| US5699798A (en) | 1990-08-10 | 1997-12-23 | University Of Washington | Method for optically imaging solid tumor tissue |
| US5635354A (en) | 1991-01-09 | 1997-06-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for describing the repertoires of antibodies (Ab) and of T-cell receptors (TcR) of an individual's immune system |
| US5364759B2 (en) | 1991-01-31 | 1999-07-20 | Baylor College Medicine | Dna typing with short tandem repeat polymorphisms and identification of polymorphic short tandem repeats |
| CA2079881C (fr) | 1991-02-12 | 2007-11-06 | Thierry Hercend | Sequences nucleotidiques codant pour des regions variables de chaines .beta. des recepteurs des lymphocytes t humains, segments peptidiques correspondants et les applications diagnostiques et therapeutiques |
| JP3080178B2 (ja) | 1991-02-18 | 2000-08-21 | 東洋紡績株式会社 | 核酸配列の増幅方法およびそのための試薬キット |
| US6091000A (en) | 1991-03-15 | 2000-07-18 | Duke University | SCID mouse engrafted with human synovium tissue |
| JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗hiv剤 |
| US5674679A (en) | 1991-09-27 | 1997-10-07 | Amersham Life Science, Inc. | DNA cycle sequencing |
| US5981179A (en) | 1991-11-14 | 1999-11-09 | Digene Diagnostics, Inc. | Continuous amplification reaction |
| US5213960A (en) | 1992-03-09 | 1993-05-25 | Tanox Biosystems, Inc. | Methods for selecting low frequency antigen-specific single B lymphocytes |
| US5256542A (en) | 1992-03-09 | 1993-10-26 | Tanox Biosystems, Inc. | Selecting low frequency antigen-specific single B lymphocytes with correction for background noise |
| US5837447A (en) | 1992-04-15 | 1998-11-17 | Blood Center Research Foundation, Inc., The | Monitoring an immune response by analysis of amplified immunoglobulin or T-cell-receptor nucleic acid |
| US5587128A (en) | 1992-05-01 | 1996-12-24 | The Trustees Of The University Of Pennsylvania | Mesoscale polynucleotide amplification devices |
| US5498392A (en) | 1992-05-01 | 1996-03-12 | Trustees Of The University Of Pennsylvania | Mesoscale polynucleotide amplification device and method |
| CA2135073C (en) | 1992-05-06 | 2002-11-19 | Daniel L. Kacian | Nucleic acid sequence amplification method, composition and kit |
| US5981176A (en) | 1992-06-17 | 1999-11-09 | City Of Hope | Method of detecting and discriminating between nucleic acid sequences |
| US5925517A (en) | 1993-11-12 | 1999-07-20 | The Public Health Research Institute Of The City Of New York, Inc. | Detectably labeled dual conformation oligonucleotide probes, assays and kits |
| EP0753060A4 (en) | 1994-04-18 | 1999-11-24 | New York Society | PRESERVED T CELL RECEPTOR SEQUENCES |
| US6001229A (en) | 1994-08-01 | 1999-12-14 | Lockheed Martin Energy Systems, Inc. | Apparatus and method for performing microfluidic manipulations for chemical analysis |
| US6090592A (en) | 1994-08-03 | 2000-07-18 | Mosaic Technologies, Inc. | Method for performing amplification of nucleic acid on supports |
| FR2724182B1 (fr) | 1994-09-02 | 1996-12-13 | Pasteur Institut | Obtention d'un anticorps monoclonal recombinant a partir d'un anticorps monoclonal humain anti-rhesus d, sa production en cellules d'insecte, et ses utilisations |
| US5846719A (en) | 1994-10-13 | 1998-12-08 | Lynx Therapeutics, Inc. | Oligonucleotide tags for sorting and identification |
| US5604097A (en) | 1994-10-13 | 1997-02-18 | Spectragen, Inc. | Methods for sorting polynucleotides using oligonucleotide tags |
| US5776737A (en) | 1994-12-22 | 1998-07-07 | Visible Genetics Inc. | Method and composition for internal identification of samples |
| US6919434B1 (en) | 1995-02-20 | 2005-07-19 | Sankyo Co., Ltd. | Monoclonal antibodies that bind OCIF |
| US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
| WO1997013877A1 (en) | 1995-10-12 | 1997-04-17 | Lynx Therapeutics, Inc. | Measurement of gene expression profiles in toxicity determination |
| US6087096A (en) | 1995-11-13 | 2000-07-11 | Dau; Peter C. | Method of intrafamily fragment analysis of the T cell receptor α and β chain CDR3 regions |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| US20020076725A1 (en) | 1996-03-13 | 2002-06-20 | Tomoko Toyosaki-Maeda | Human t cell clone specific for rheumatoid arthritis |
| US6458530B1 (en) | 1996-04-04 | 2002-10-01 | Affymetrix Inc. | Selecting tag nucleic acids |
| US6416948B1 (en) | 1996-06-03 | 2002-07-09 | The Governors Of The University Of Alberta | Methods for detection of rearranged DNA |
| DE69739357D1 (de) | 1996-06-04 | 2009-05-28 | Univ Utah Res Found | Überwachung der hybridisierung während pcr |
| WO1998001738A2 (en) | 1996-06-20 | 1998-01-15 | Cornell Research Foundation, Inc. | Identification of abnormalities in the expression of t and b cell antigen receptors as disease indicators |
| US6074827A (en) | 1996-07-30 | 2000-06-13 | Aclara Biosciences, Inc. | Microfluidic method for nucleic acid purification and processing |
| EP0937251B1 (en) | 1996-09-06 | 2006-11-29 | Ortho-McNeil Pharmaceutical, Inc. | Purification of antigen-specific t cells |
| WO1998015644A2 (en) | 1996-09-27 | 1998-04-16 | The Chinese University Of Hong Kong | Parallel polynucleotide sequencing method |
| GB9626815D0 (en) | 1996-12-23 | 1997-02-12 | Cemu Bioteknik Ab | Method of sequencing DNA |
| GB9704444D0 (en) | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
| ATE364718T1 (de) | 1997-04-01 | 2007-07-15 | Solexa Ltd | Verfahren zur vervielfältigung von nukleinsäure |
| US6143496A (en) | 1997-04-17 | 2000-11-07 | Cytonix Corporation | Method of sampling, amplifying and quantifying segment of nucleic acid, polymerase chain reaction assembly having nanoliter-sized sample chambers, and method of filling assembly |
| DK1019496T3 (da) | 1997-07-07 | 2005-01-10 | Medical Res Council | In vitro-sorteringsmetode |
| US7572582B2 (en) | 1997-09-12 | 2009-08-11 | Exiqon A/S | Oligonucleotide analogues |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US6803019B1 (en) | 1997-10-15 | 2004-10-12 | Aclara Biosciences, Inc. | Laminate microstructure device and method for making same |
| JP2001520054A (ja) | 1997-10-23 | 2001-10-30 | エグザクト サイエンシーズ コーポレイション | Pcrを用いる分子診断におけるコンタミネーションを検出するための方法 |
| US7351578B2 (en) | 1999-12-10 | 2008-04-01 | Invitrogen Corp. | Use of multiple recombination sites with unique specificity in recombinational cloning |
| US6210910B1 (en) | 1998-03-02 | 2001-04-03 | Trustees Of Tufts College | Optical fiber biosensor array comprising cell populations confined to microcavities |
| JP4262799B2 (ja) | 1998-04-16 | 2009-05-13 | 平田機工株式会社 | 生タイヤ供給方法 |
| DE19833738A1 (de) | 1998-07-27 | 2000-02-03 | Michael Giesing | Verfahren zur Isolierung von Krebszellen aus zellhaltigen Körperflüssigkeiten sowie Sets zur Durchführung dieses Verfahrens |
| US6787308B2 (en) | 1998-07-30 | 2004-09-07 | Solexa Ltd. | Arrayed biomolecules and their use in sequencing |
| DE19844931C1 (de) | 1998-09-30 | 2000-06-15 | Stefan Seeger | Verfahren zur DNS- oder RNS-Sequenzierung |
| AR021833A1 (es) | 1998-09-30 | 2002-08-07 | Applied Research Systems | Metodos de amplificacion y secuenciacion de acido nucleico |
| US6541608B1 (en) | 1999-02-23 | 2003-04-01 | Baylor College Of Medicine | T cell receptor Vβ-Dβ-Jβ sequence and methods for its detection |
| US6307024B1 (en) | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| US6300070B1 (en) | 1999-06-04 | 2001-10-09 | Mosaic Technologies, Inc. | Solid phase methods for amplifying multiple nucleic acids |
| US6440706B1 (en) | 1999-08-02 | 2002-08-27 | Johns Hopkins University | Digital amplification |
| US20040209314A1 (en) | 1999-09-06 | 2004-10-21 | Institut National De La Sante Et De La Recherche Medicale France | Means for detection and purification of CD8+ T lymphocyte populations specific to peptides presented in the context of HLA |
| US6235483B1 (en) | 2000-01-31 | 2001-05-22 | Agilent Technologies, Inc. | Methods and kits for indirect labeling of nucleic acids |
| JP2004505612A (ja) | 2000-03-31 | 2004-02-26 | ユニバーシティ・オブ・サザン・カリフォルニア | 食道腺ガンに関する後成的配列 |
| AUPQ687600A0 (en) | 2000-04-13 | 2000-05-11 | Flinders Technologies Pty Ltd | A method of detection |
| US20030207300A1 (en) | 2000-04-28 | 2003-11-06 | Matray Tracy J. | Multiplex analytical platform using molecular tags |
| US6596492B2 (en) | 2000-07-11 | 2003-07-22 | Colorado State University Research Foundation | PCR materials and methods useful to detect canine and feline lymphoid malignancies |
| US7567870B1 (en) | 2000-07-31 | 2009-07-28 | Institute For Systems Biology | Multiparameter analysis for predictive medicine |
| US6939451B2 (en) | 2000-09-19 | 2005-09-06 | Aclara Biosciences, Inc. | Microfluidic chip having integrated electrodes |
| AU2002246612B2 (en) | 2000-10-24 | 2007-11-01 | The Board Of Trustees Of The Leland Stanford Junior University | Direct multiplex characterization of genomic DNA |
| US6778724B2 (en) | 2000-11-28 | 2004-08-17 | The Regents Of The University Of California | Optical switching and sorting of biological samples and microparticles transported in a micro-fluidic device, including integrated bio-chip devices |
| ATE488576T1 (de) | 2001-02-20 | 2010-12-15 | Univ Georgia | Schnellproduktion monoklonaler antikörper |
| US7265208B2 (en) | 2001-05-01 | 2007-09-04 | The Regents Of The University Of California | Fusion molecules and treatment of IgE-mediated allergic diseases |
| WO2002094009A2 (en) | 2001-05-24 | 2002-11-28 | Guard Inc. | Methods for selecting and producing animals having a predicted level of immune response |
| US20050260570A1 (en) | 2001-05-29 | 2005-11-24 | Mao Jen-I | Sequencing by proxy |
| US6720144B1 (en) | 2001-06-21 | 2004-04-13 | Quest Diagnostics | Detection of clonal T-cell receptor-γ gene rearrangement by PCR/temporal temperature gradient gel electrophoresis (TTGE) |
| AU2002313683A1 (en) | 2001-07-15 | 2003-03-03 | Keck Graduate Institute | Nucleic acid amplification using nicking agents |
| US20030096277A1 (en) | 2001-08-30 | 2003-05-22 | Xiangning Chen | Allele specific PCR for genotyping |
| WO2003020979A1 (en) | 2001-08-31 | 2003-03-13 | Rosetta Inpharmactis Llc. | Methods for preparing nucleic acid samples |
| ATE290020T1 (de) | 2001-08-31 | 2005-03-15 | Avidex Ltd | Löslicher t zell rezeptor |
| DE60234369D1 (de) | 2001-09-19 | 2009-12-24 | Alexion Pharma Inc | Manipulierte matrizen und ihre verwendung bei der single-primer-amplifikation |
| US6964850B2 (en) | 2001-11-09 | 2005-11-15 | Source Precision Medicine, Inc. | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
| GB2382137A (en) | 2001-11-20 | 2003-05-21 | Mats Gullberg | Nucleic acid enrichment |
| GB0128153D0 (en) | 2001-11-23 | 2002-01-16 | Bayer Ag | Profiling of the immune gene repertoire |
| WO2003052101A1 (en) | 2001-12-14 | 2003-06-26 | Rosetta Inpharmatics, Inc. | Sample tracking using molecular barcodes |
| GB0130267D0 (en) | 2001-12-19 | 2002-02-06 | Neutec Pharma Plc | Focussed antibody technology |
| WO2003059155A2 (en) | 2002-01-09 | 2003-07-24 | Maxx Genetech Co. Ltd | Method of detecting t-cell proliferation for diagnosis of diseases by gene array |
| US7157274B2 (en) | 2002-06-24 | 2007-01-02 | Cytonome, Inc. | Method and apparatus for sorting particles |
| CA2485968A1 (en) | 2002-05-16 | 2004-06-03 | Vanderbilt University | Method for predicting autoimmune diseases |
| EP1573636A2 (en) | 2002-07-01 | 2005-09-14 | Institut Pasteur | System, method, device, and computer program product for extraction, gathering, manipulation, and analysis of peak data from an automated sequencer |
| US7691994B2 (en) | 2002-07-03 | 2010-04-06 | Brewer Jamie L | Compositions and methods for the detection of human T cell receptor variable family gene expression |
| CA2800113C (en) | 2002-07-12 | 2015-02-03 | The Johns Hopkins University | Reagents and methods for engaging unique clonotypic lymphocyte receptors |
| WO2004009765A2 (en) | 2002-07-19 | 2004-01-29 | Althea Technologies, Inc. | Strategies for gene expression analysis |
| US7157228B2 (en) | 2002-09-09 | 2007-01-02 | Bioarray Solutions Ltd. | Genetic analysis and authentication |
| AU2003283963A1 (en) | 2002-09-27 | 2004-04-19 | Ludwig Institute For Cancer Research | Mage-c2 antigenic peptides and uses thereof |
| US7459273B2 (en) | 2002-10-04 | 2008-12-02 | Affymetrix, Inc. | Methods for genotyping selected polymorphism |
| WO2004034031A2 (en) | 2002-10-11 | 2004-04-22 | The Regents Of The University Of California | A method for diagnosis and prognosis of multiple sclerosis |
| EP2460889B1 (en) | 2002-10-11 | 2013-11-20 | Erasmus Universiteit Rotterdam | Nucleic acid amplification primers for PCR-based clonality studies of BCL2-IGH rearrangements |
| US20060147925A1 (en) | 2002-11-13 | 2006-07-06 | Morley Alexander A | Method of detection |
| EP1566635B1 (en) | 2002-11-14 | 2011-12-07 | Vivalis | Microwell array chip for detecting antigen-specific lymphocyte, method of detecting antigen-specific lymphocyte and method of cloning antigen-specific lymphocyte antigen receptor gene |
| AU2003300919A1 (en) | 2002-12-11 | 2004-06-30 | Coley Pharmaceutical Gmbh | 5' cpg nucleic acids and methods of use |
| WO2004063706A2 (en) | 2003-01-08 | 2004-07-29 | Maxx Genetech Co., Ltd. | Method of detecting over-expression of t-cell receptor genes by real-time pcr |
| EP1594950A4 (en) | 2003-01-29 | 2007-07-25 | 454 Corp | PRODUCT FOR THE PREPARATION OF SIMPLE STRANDED DNA BANKS |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| WO2004096985A2 (en) | 2003-04-24 | 2004-11-11 | Mayo Foundation For Medical Education And Research | Methods for assessing biologic diversity |
| AU2003902299A0 (en) | 2003-05-13 | 2003-05-29 | Flinders Medical Centre | A method of analysing a marker nucleic acid molecule |
| US20070105105A1 (en) | 2003-05-23 | 2007-05-10 | Mount Sinai School Of Medicine Of New York University | Surrogate cell gene expression signatures for evaluating the physical state of a subject |
| US20050010030A1 (en) | 2003-07-02 | 2005-01-13 | Zang Jingwu Z. | T cell receptor CDR3 sequence and methods for detecting and treating rheumatoid arthritis |
| CA2531105C (en) | 2003-07-05 | 2015-03-17 | The Johns Hopkins University | Method and compositions for detection and enumeration of genetic variations |
| US20060228350A1 (en) | 2003-08-18 | 2006-10-12 | Medimmune, Inc. | Framework-shuffling of antibodies |
| US20050048498A1 (en) | 2003-08-29 | 2005-03-03 | Applera Corporation | Compositions, methods, and kits for assembling probes |
| US7365179B2 (en) | 2003-09-09 | 2008-04-29 | Compass Genetics, Llc | Multiplexed analytical platform |
| TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
| FR2863274B1 (fr) | 2003-12-05 | 2012-11-16 | Commissariat Energie Atomique | Procede d'evaluation quantitative d'un rearrangement ou d'une recombinaison genetique ciblee d'un individu et ses applications. |
| WO2005053603A2 (en) | 2003-12-08 | 2005-06-16 | Yeda Research And Development Co. Ltd. | Antigen receptor variable region typing |
| ATE421998T1 (de) | 2003-12-15 | 2009-02-15 | Pasteur Institut | Ermittlung des repertoires von b-lymphozyten populationen |
| US20080166718A1 (en) | 2003-12-15 | 2008-07-10 | Institut Pasteur | Repertoire determination of a lymphocyte B population |
| US20070160994A1 (en) | 2003-12-15 | 2007-07-12 | Institut Pasteur | Repertoire determination of a lymphocyte b population |
| EP1721014B1 (en) | 2004-02-18 | 2013-07-17 | Trustees Of Boston University | Method for detecting and quantifying rare mutations/polymorphisms |
| US20060046258A1 (en) | 2004-02-27 | 2006-03-02 | Lapidus Stanley N | Applications of single molecule sequencing |
| US20070161001A1 (en) | 2004-03-04 | 2007-07-12 | Dena Leshkowitz | Quantifying and profiling antibody and t cell receptor gene expression |
| JP4480423B2 (ja) | 2004-03-08 | 2010-06-16 | 独立行政法人科学技術振興機構 | 免疫細胞クローンの拡大の有無の判定方法 |
| DE102004016437A1 (de) | 2004-04-04 | 2005-10-20 | Oligene Gmbh | Verfahren zur Erkennung von Signaturen in komplexen Genexpressionsprofilen |
| US20050250147A1 (en) | 2004-05-10 | 2005-11-10 | Macevicz Stephen C | Digital profiling of polynucleotide populations |
| WO2006076025A2 (en) | 2004-05-14 | 2006-07-20 | Amaox, Inc. | Immune cell biosensors and methods of using same |
| EP1598429A1 (en) | 2004-05-19 | 2005-11-23 | Amplion Ltd. | Detection of amplicon contamination during PCR exhibiting two different annealing temperatures |
| GB0412973D0 (en) | 2004-06-10 | 2004-07-14 | Celltech R&D Ltd | Identification of antibody producing cells |
| US20060020397A1 (en) | 2004-07-21 | 2006-01-26 | Kermani Bahram G | Methods for nucleic acid and polypeptide similarity search employing content addressable memories |
| US20060019304A1 (en) | 2004-07-26 | 2006-01-26 | Paul Hardenbol | Simultaneous analysis of multiple genomes |
| US7820382B2 (en) | 2004-08-03 | 2010-10-26 | Bauer A Robert | Method for the early detection of breast cancer, lung cancer, pancreatic cancer and colon polyps, growths and cancers as well as other gastrointestinal disease conditions and the preoperative and postoperative monitoring of transplanted organs from the donor and in the recipient and their associated conditions related and unrelated to the organ transplantation |
| US20060094018A1 (en) | 2004-08-03 | 2006-05-04 | Bauer A R Jr | Discovery and a method for the early detection of pancreatic cancer and other disease conditions |
| ME01803B (me) | 2004-08-05 | 2010-12-31 | Genentech Inc | Humanizovani anti-cmet antagonisti |
| CA2580412A1 (en) | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Compositions comprising t cell receptors and methods of use thereof |
| US7170050B2 (en) | 2004-09-17 | 2007-01-30 | Pacific Biosciences Of California, Inc. | Apparatus and methods for optical analysis of molecules |
| WO2006050138A2 (en) | 2004-10-29 | 2006-05-11 | Benaroya Research Institute At Virginia Mason | Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use |
| US7966988B2 (en) | 2005-01-11 | 2011-06-28 | Exxonmobil Research And Engineering Company | Method for controlling soot induced lubricant viscosity increase |
| US8029783B2 (en) | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
| FR2881436B1 (fr) | 2005-02-03 | 2007-04-27 | Commissariat Energie Atomique | Procede de determination de la diversite des lymphocytes t dans un echantillon biologique |
| US7393665B2 (en) | 2005-02-10 | 2008-07-01 | Population Genetics Technologies Ltd | Methods and compositions for tagging and identifying polynucleotides |
| CA2598025A1 (en) | 2005-02-16 | 2006-08-24 | Wyeth | Methods and systems for diagnosis, prognosis and selection of treatment of leukemia |
| US7537894B2 (en) | 2005-03-02 | 2009-05-26 | The University Of Chicago | Methods and kits for monitoring Barrett's metaplasia |
| WO2006099164A2 (en) | 2005-03-10 | 2006-09-21 | Applera Corporation | Methods for multiplex amplification |
| US20060211030A1 (en) | 2005-03-16 | 2006-09-21 | Sydney Brenner | Methods and compositions for assay readouts on multiple analytical platforms |
| JP2008538496A (ja) | 2005-04-12 | 2008-10-30 | 454 ライフ サイエンシーズ コーポレイション | ウルトラディープ配列決定を用いて配列変異体を決定するための方法 |
| WO2006116155A2 (en) | 2005-04-21 | 2006-11-02 | The Regents Of The University Of California | A method for diagnosis and prognosis of multiple sclerosis subtypes |
| US20060263789A1 (en) | 2005-05-19 | 2006-11-23 | Robert Kincaid | Unique identifiers for indicating properties associated with entities to which they are attached, and methods for using |
| US7208795B2 (en) | 2005-05-24 | 2007-04-24 | Atmel Corporation | Low-cost, low-voltage single-layer polycrystalline EEPROM memory cell integration into BiCMOS technology |
| US8426146B2 (en) | 2005-06-03 | 2013-04-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Multiparameteric method for assessing immune system status |
| US20090264299A1 (en) | 2006-02-24 | 2009-10-22 | Complete Genomics, Inc. | High throughput genome sequencing on DNA arrays |
| CA2611671C (en) | 2005-06-15 | 2013-10-08 | Callida Genomics, Inc. | Single molecule arrays for genetic and chemical analysis |
| WO2007008759A2 (en) | 2005-07-07 | 2007-01-18 | Hematologics, Inc. | Methods for detecting and confirming minimal disease in a cancer patient |
| US20070020640A1 (en) | 2005-07-21 | 2007-01-25 | Mccloskey Megan L | Molecular encoding of nucleic acid templates for PCR and other forms of sequence analysis |
| GB0521521D0 (en) | 2005-10-21 | 2005-11-30 | Medical Res Council | Diagnostic methods and kits |
| GB0522310D0 (en) | 2005-11-01 | 2005-12-07 | Solexa Ltd | Methods of preparing libraries of template polynucleotides |
| US20070105165A1 (en) | 2005-11-04 | 2007-05-10 | Charles Goolsby | Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers |
| US7375211B2 (en) | 2005-11-18 | 2008-05-20 | Kou Zhong C | Method for detection and quantification of T-cell receptor Vβ repertoire |
| US8137936B2 (en) | 2005-11-29 | 2012-03-20 | Macevicz Stephen C | Selected amplification of polynucleotides |
| US7544473B2 (en) | 2006-01-23 | 2009-06-09 | Population Genetics Technologies Ltd. | Nucleic acid analysis using sequence tokens |
| WO2007087312A2 (en) | 2006-01-23 | 2007-08-02 | Population Genetics Technologies Ltd. | Molecular counting |
| AU2007222798A1 (en) | 2006-03-06 | 2007-09-13 | Symphogen A/S | Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections |
| ES2546848T3 (es) | 2006-03-10 | 2015-09-29 | Epigenomics Ag | Un método para identificar una muestra biológica para el análisis de la metilación |
| JP5389638B2 (ja) | 2006-04-04 | 2014-01-15 | キージーン ナムローゼ フェンノートシャップ | 制限断片に基づく分子マーカーのハイスループットな検出 |
| CA2652086A1 (en) | 2006-05-11 | 2007-11-22 | University Of Maryland Biotechnology Institute | A general method for generating human antibody responses in vitro |
| WO2007136518A2 (en) | 2006-05-17 | 2007-11-29 | Torrey Pines Institute For Molecular Studies | Treatment of autoimmune disorders |
| WO2007139584A2 (en) | 2006-05-25 | 2007-12-06 | Institute For Advanced Study | Methods for identifying sequence motifs, and applications thereof |
| US7833716B2 (en) | 2006-06-06 | 2010-11-16 | Gen-Probe Incorporated | Tagged oligonucleotides and their use in nucleic acid amplification methods |
| JP2009539411A (ja) | 2006-06-12 | 2009-11-19 | パシフィック バイオサイエンシーズ オブ カリフォルニア, インコーポレイテッド | 分析反応を行うための基板 |
| US20100027896A1 (en) | 2006-06-28 | 2010-02-04 | Amir Geva | Automated application interaction using a virtual operator |
| US7553949B2 (en) | 2006-06-30 | 2009-06-30 | Applied Biosystems, Llc | Reversible terminator nucleotides and methods of use |
| WO2008108803A2 (en) | 2006-07-13 | 2008-09-12 | Amaox, Ltd. | Immune cell biosensors and methods of using same |
| US8394590B2 (en) | 2006-08-02 | 2013-03-12 | California Institute Of Technology | Capture agents and related methods and systems for detecting and/or sorting targets |
| US20080274904A1 (en) | 2006-08-10 | 2008-11-06 | Niall Anthony Gormley | Method of target enrichment |
| WO2008026927A2 (en) | 2006-08-30 | 2008-03-06 | Academisch Medisch Centrum | Process for displaying t- and b-cell receptor repertoires |
| WO2008039694A2 (en) | 2006-09-26 | 2008-04-03 | St. Jude Children's Research Hospital | Methods and compositions for monitoring t cell receptor diversity |
| US8088379B2 (en) | 2006-09-26 | 2012-01-03 | The United States Of America As Represented By The Department Of Health And Human Services | Modified T cell receptors and related materials and methods |
| JP5026047B2 (ja) | 2006-10-18 | 2012-09-12 | 株式会社膠原病研究所 | 自己免疫疾患の発症に関わる自己応答性t細胞またはt細胞受容体の同定方法、およびその利用 |
| US8148067B2 (en) | 2006-11-09 | 2012-04-03 | Xdx, Inc. | Methods for diagnosing and monitoring the status of systemic lupus erythematosus |
| US8262900B2 (en) | 2006-12-14 | 2012-09-11 | Life Technologies Corporation | Methods and apparatus for measuring analytes using large scale FET arrays |
| US7862999B2 (en) | 2007-01-17 | 2011-01-04 | Affymetrix, Inc. | Multiplex targeted amplification using flap nuclease |
| RU2459868C2 (ru) | 2007-03-01 | 2012-08-27 | Симфоген А/С | Способ клонирования когнатных антител |
| WO2008147879A1 (en) | 2007-05-22 | 2008-12-04 | Ryan Golhar | Automated method and device for dna isolation, sequence determination, and identification |
| CN101720359A (zh) | 2007-06-01 | 2010-06-02 | 454生命科学公司 | 从多重混合物中识别个别样本的系统和方法 |
| US8454906B2 (en) | 2007-07-24 | 2013-06-04 | The Regents Of The University Of California | Microfabricated droplet generator for single molecule/cell genetic analysis in engineered monodispersed emulsions |
| ITRM20070429A1 (it) | 2007-08-06 | 2009-02-07 | Uni Cattolica Del Sacro Cuor E | Mezzi per la diagnosi la prevenzione e la cura dell'artrite reumatoide. |
| US20090042737A1 (en) | 2007-08-09 | 2009-02-12 | Katz Andrew S | Methods and Devices for Correlated, Multi-Parameter Single Cell Measurements and Recovery of Remnant Biological Material |
| US8268564B2 (en) | 2007-09-26 | 2012-09-18 | President And Fellows Of Harvard College | Methods and applications for stitched DNA barcodes |
| US7960116B2 (en) | 2007-09-28 | 2011-06-14 | Pacific Biosciences Of California, Inc. | Nucleic acid sequencing methods and systems |
| US20100285984A1 (en) * | 2007-09-28 | 2010-11-11 | Wettstein Peter J | Assessing t cell repertoires |
| BRPI0820707A2 (pt) | 2007-11-07 | 2015-06-16 | Genentech Inc | Métodos e composição para avaliar a responsividade do linfoma de células b para o tratamento com anticorpos anti-cd40 |
| WO2009070767A2 (en) | 2007-11-28 | 2009-06-04 | Whitehead Institute For Biomedical Research | Systemic instigation systems to study tumor growth or metastasis |
| EP2062982A1 (fr) | 2007-11-26 | 2009-05-27 | ImmunID | Procédé d'étude de la diversité combinatoire V(D)J |
| CN101225441B (zh) | 2007-12-05 | 2010-12-01 | 浙江大学 | 一种检测克隆特异性t淋巴细胞tcr bv cdr3基因组成的方法 |
| US8621502B2 (en) | 2007-12-21 | 2013-12-31 | Microsoft Corporation | Obtaining user reactions to video |
| US7767400B2 (en) | 2008-02-03 | 2010-08-03 | Helicos Biosciences Corporation | Paired-end reads in sequencing by synthesis |
| EP2088205A1 (en) | 2008-02-11 | 2009-08-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | PSMB10: A diagnosis marker and therapeutic target of chronic rejection. |
| EP2088432A1 (en) | 2008-02-11 | 2009-08-12 | MorphoSys AG | Methods for identification of an antibody or a target |
| CN104031984A (zh) | 2008-02-28 | 2014-09-10 | 俄亥俄州立大学研究基金会 | 用于前列腺相关病症的诊断、预后和治疗的基于微rna的方法和组合物 |
| EP2250496A4 (en) | 2008-02-28 | 2011-08-31 | Univ Ohio State Res Found | MICRO-RNA SIGNATURES ASSOCIATED WITH CYTOGENETICS AND PROGNOSIS IN ACUTE MYELOID LEUKEMIA (AML) AND USES THEREOF |
| US20090226975A1 (en) | 2008-03-10 | 2009-09-10 | Illumina, Inc. | Constant cluster seeding |
| TW200938840A (en) | 2008-03-12 | 2009-09-16 | Emo Biomedicine Corp | A method for in vitro study of immune modulation using pig blood cell |
| EP2100970B1 (en) | 2008-03-13 | 2017-05-10 | National Institute of Immunology | Ig genes specific oligonucleotides and uses thereof |
| EP3045542B1 (en) | 2008-03-28 | 2016-11-16 | Pacific Biosciences of California, Inc. | Methods for nucleic acid sequencing |
| EP2107040B1 (en) | 2008-03-31 | 2011-10-26 | Sony Deutschland Gmbh | A method of fabricating a membrane having a tapered pore |
| EP2281065B1 (en) | 2008-04-16 | 2015-09-09 | HudsonAlpha Institute For Biotechnology | Method for evaluating and comparing immunorepertoires |
| US8911948B2 (en) | 2008-04-30 | 2014-12-16 | Integrated Dna Technologies, Inc. | RNase H-based assays utilizing modified RNA monomers |
| WO2009137832A2 (en) | 2008-05-09 | 2009-11-12 | Duke University | Autoantibodies in the detection and treatment of cancer |
| US9068181B2 (en) | 2008-05-23 | 2015-06-30 | The General Hospital Corporation | Microfluidic droplet encapsulation |
| WO2009145925A1 (en) | 2008-05-30 | 2009-12-03 | Massachusetts Institute Of Technology | Compositions and methods for spatial separation and screening of cells |
| WO2009151628A2 (en) | 2008-06-12 | 2009-12-17 | Gov't Of The Usa, As Represented By The Secretary, Department Of Health Human Services | Monitoring tcr-b to determine hiv therapy and disease progression |
| SG182951A1 (en) | 2008-06-25 | 2012-08-30 | Baylor Res Inst | Blood transcriptional signature of mycobacterium tuberculosis infection |
| US8394583B2 (en) | 2008-07-24 | 2013-03-12 | The Board Of Regents Of The University Of Texas System | VH4 codon signature for multiple sclerosis |
| KR20110036638A (ko) | 2008-07-25 | 2011-04-07 | 리차드 더블유. 와그너 | 단백질 스크리닝 방법 |
| US9156010B2 (en) | 2008-09-23 | 2015-10-13 | Bio-Rad Laboratories, Inc. | Droplet-based assay system |
| CA2738578C (en) | 2008-09-23 | 2021-05-04 | Quantalife, Inc. | Droplet-based assay system |
| US8699361B2 (en) | 2008-09-30 | 2014-04-15 | Qualcomm Incorporated | Out-of-synchronization handling method and apparatus |
| US8546128B2 (en) | 2008-10-22 | 2013-10-01 | Life Technologies Corporation | Fluidics system for sequential delivery of reagents |
| US20100137143A1 (en) | 2008-10-22 | 2010-06-03 | Ion Torrent Systems Incorporated | Methods and apparatus for measuring analytes |
| US9394567B2 (en) | 2008-11-07 | 2016-07-19 | Adaptive Biotechnologies Corporation | Detection and quantification of sample contamination in immune repertoire analysis |
| US9365901B2 (en) | 2008-11-07 | 2016-06-14 | Adaptive Biotechnologies Corp. | Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia |
| US8691510B2 (en) | 2008-11-07 | 2014-04-08 | Sequenta, Inc. | Sequence analysis of complex amplicons |
| US9528160B2 (en) | 2008-11-07 | 2016-12-27 | Adaptive Biotechnolgies Corp. | Rare clonotypes and uses thereof |
| US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
| US9506119B2 (en) | 2008-11-07 | 2016-11-29 | Adaptive Biotechnologies Corp. | Method of sequence determination using sequence tags |
| US8748103B2 (en) | 2008-11-07 | 2014-06-10 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
| US20140234835A1 (en) | 2008-11-07 | 2014-08-21 | Sequenta, Inc. | Rare clonotypes and uses thereof |
| CN102272327B (zh) | 2008-11-07 | 2015-11-25 | 赛昆塔公司 | 通过序列分析监测状况的方法 |
| WO2010060051A2 (en) | 2008-11-21 | 2010-05-27 | Emory University | Systems biology approach predicts the immunogenicity of vaccines |
| US8367330B2 (en) | 2008-12-22 | 2013-02-05 | Quest Diagnostics Investments Incorporated | Methods for detecting TCR-gamma gene rearrangement |
| CN102272326B (zh) | 2008-12-30 | 2014-11-12 | 森托科尔奥索生物科技公司 | 预测强直性脊柱炎患者对于抗TNFα抗体的临床反应的血清标记物 |
| DK2387627T3 (da) | 2009-01-15 | 2016-07-04 | Adaptive Biotechnologies Corp | Adaptiv immunitetsprofilering og fremgangsmåder til at frembringe monoklonale antistoffer |
| CN102333891A (zh) | 2009-01-20 | 2012-01-25 | 利兰·斯坦福青年大学托管委员会 | 用于药靶诊断、预后和鉴别的单细胞基因表达 |
| US20100323348A1 (en) | 2009-01-31 | 2010-12-23 | The Regents Of The University Of Colorado, A Body Corporate | Methods and Compositions for Using Error-Detecting and/or Error-Correcting Barcodes in Nucleic Acid Amplification Process |
| US8574835B2 (en) | 2009-05-29 | 2013-11-05 | Life Technologies Corporation | Scaffolded nucleic acid polymer particles and methods of making and using |
| US8673627B2 (en) | 2009-05-29 | 2014-03-18 | Life Technologies Corporation | Apparatus and methods for performing electrochemical reactions |
| RU2539032C2 (ru) | 2009-06-25 | 2015-01-10 | Фред Хатчинсон Кансэр Рисёч Сентер | Способ измерения искусственного иммунитета |
| US8497071B2 (en) | 2009-06-29 | 2013-07-30 | California Institute Of Technology | Isolation of unknown rearranged T-cell receptors from single cells |
| WO2011035870A1 (en) | 2009-09-22 | 2011-03-31 | Roche Diagnostics Gmbh | Determination of kir haplotypes associated with disease |
| US9043160B1 (en) | 2009-11-09 | 2015-05-26 | Sequenta, Inc. | Method of determining clonotypes and clonotype profiles |
| US8835358B2 (en) | 2009-12-15 | 2014-09-16 | Cellular Research, Inc. | Digital counting of individual molecules by stochastic attachment of diverse labels |
| US9315857B2 (en) | 2009-12-15 | 2016-04-19 | Cellular Research, Inc. | Digital counting of individual molecules by stochastic attachment of diverse label-tags |
| US8545248B2 (en) | 2010-01-07 | 2013-10-01 | Life Technologies Corporation | System to control fluid flow based on a leak detected by a sensor |
| KR101323827B1 (ko) | 2010-01-08 | 2013-10-31 | 키스트 유럽 에프게엠베하 | 강직성척추염 진단용 프라이머 및 이를 이용한 강직성 척추염 진단 방법 |
| GB201000375D0 (en) | 2010-01-09 | 2010-02-24 | Univ Cardiff | T Cell clonotypes |
| US9410205B2 (en) * | 2010-02-18 | 2016-08-09 | New York University | Methods for predicting survival in metastatic melanoma patients |
| WO2011106738A2 (en) | 2010-02-25 | 2011-09-01 | Fred Hutchinson Cancer Research Center | Use of tcr clonotypes as biomarkers for disease |
| EP2367000A1 (en) | 2010-03-04 | 2011-09-21 | Charité Universitätsmedizin Berlin | High throughput analysis of T-cell receptor repertoires |
| SG10201503534RA (en) | 2010-05-06 | 2015-06-29 | Sequenta Inc | Monitoring health and disease status using clonotype profiles |
| CA2796822C (en) | 2010-05-07 | 2021-10-05 | The Board Of Trustees Of The Leland Standford Junior University | Measurement and comparison of immune diversity by high-throughput sequencing |
| US20130123120A1 (en) | 2010-05-18 | 2013-05-16 | Natera, Inc. | Highly Multiplex PCR Methods and Compositions |
| EP3290529B1 (en) | 2010-06-11 | 2019-05-22 | Life Technologies Corporation | Alternative nucleotide flows in sequencing-by-synthesis methods |
| WO2012027503A2 (en) | 2010-08-24 | 2012-03-01 | Fred Hutchinson Cancer Research Center | Method of measuring adaptive immunity |
| EP3115468B1 (en) | 2010-09-21 | 2018-07-25 | Agilent Technologies, Inc. | Increasing confidence of allele calls with molecular counting |
| WO2012045012A2 (en) | 2010-09-30 | 2012-04-05 | Raindance Technologies, Inc. | Sandwich assays in droplets |
| ES2730951T3 (es) | 2010-10-08 | 2019-11-13 | Harvard College | Secuenciación inmune de alto rendimiento |
| WO2012048341A1 (en) | 2010-10-08 | 2012-04-12 | President And Fellows Of Harvard College | High-throughput single cell barcoding |
| US8753816B2 (en) | 2010-10-26 | 2014-06-17 | Illumina, Inc. | Sequencing methods |
| AU2011323107B2 (en) | 2010-11-05 | 2015-09-10 | Illumina, Inc. | Linking sequence reads using paired code tags |
| WO2012083069A2 (en) | 2010-12-15 | 2012-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Measurement and monitoring of cell clonality |
| US20140057799A1 (en) | 2010-12-16 | 2014-02-27 | Gigagen | System and Methods for Massively Parallel Analysis of Nucleic Acids in Single Cells |
| WO2012118555A1 (en) | 2010-12-29 | 2012-09-07 | Life Technologies Corporation | Time-warped background signal for sequencing-by-synthesis operations |
| EP2658999B1 (en) | 2010-12-30 | 2019-03-13 | Life Technologies Corporation | Models for analyzing data from sequencing-by-synthesis operations |
| CA2824854A1 (en) * | 2011-01-14 | 2012-07-19 | Cb Biotechnologies, Inc. | Immunodiversity assessment method and its use |
| US8759036B2 (en) | 2011-03-21 | 2014-06-24 | Affymetrix, Inc. | Methods for synthesizing pools of probes |
| AU2012242847B2 (en) | 2011-04-15 | 2017-01-19 | The Johns Hopkins University | Safe sequencing system |
| HRP20230443T1 (hr) | 2011-05-24 | 2023-09-15 | BioNTech SE | Individualizirana cjepiva protiv raka |
| US9834766B2 (en) | 2011-09-02 | 2017-12-05 | Atreca, Inc. | DNA barcodes for multiplexed sequencing |
| US20140356339A1 (en) * | 2011-09-09 | 2014-12-04 | Sequenta Inc. | Sequence-based measures of immune response |
| US10385475B2 (en) | 2011-09-12 | 2019-08-20 | Adaptive Biotechnologies Corp. | Random array sequencing of low-complexity libraries |
| US20140256592A1 (en) | 2011-10-11 | 2014-09-11 | Sequenta, Inc. | Determining responsiveness of autoimmune patients to dmard treatment |
| HK1201565A1 (en) * | 2011-10-21 | 2015-09-04 | Adaptive Biotechnologies Corporation | Quantification of adaptive immune cell genomes in a complex mixture of cells |
| WO2013066726A1 (en) | 2011-11-04 | 2013-05-10 | Sequenta, Inc. | T-cell receptor clonotypes shared among ankylosing spondylitis patients |
| WO2013085855A1 (en) | 2011-12-05 | 2013-06-13 | Sequenta, Inc. | Clonotypes as biometric specimen tags |
| EP2788509B1 (en) | 2011-12-09 | 2018-07-11 | Adaptive Biotechnologies Corporation | Diagnosis of lymphoid malignancies and minimal residual disease detection |
| JP2015501644A (ja) | 2011-12-09 | 2015-01-19 | シーケンタ インコーポレイテッド | 免疫活性化を測定する方法 |
| WO2013090390A2 (en) | 2011-12-13 | 2013-06-20 | Sequenta, Inc. | Method of measuring immune activation |
| US9499865B2 (en) | 2011-12-13 | 2016-11-22 | Adaptive Biotechnologies Corp. | Detection and measurement of tissue-infiltrating lymphocytes |
| US20140349883A1 (en) | 2011-12-20 | 2014-11-27 | Sequenta, Inc. | Monitoring transformation of follicular lymphoma to diffuse large b-cell lymphoma by immune repertoire analysis |
| WO2013112655A1 (en) | 2012-01-24 | 2013-08-01 | Gigagen, Inc. | Method for correction of bias in multiplexed amplification |
| WO2013130512A2 (en) | 2012-02-27 | 2013-09-06 | The University Of North Carolina At Chapel Hill | Methods and uses for molecular tags |
| WO2013131074A1 (en) | 2012-03-02 | 2013-09-06 | Diogenix, Inc. | Methods and reagents for evaluating autoimmune disease and determining antibody repertoire |
| ES2662128T3 (es) | 2012-03-05 | 2018-04-05 | Adaptive Biotechnologies Corporation | Determinación de cadenas de receptor inmunitario emparejadas a partir de la frecuencia de subunidades coincidentes |
| WO2013134302A1 (en) | 2012-03-05 | 2013-09-12 | Sequenta, Inc. | Monitoring immune responsiveness to cancer vaccination |
| US20150038346A1 (en) | 2012-03-05 | 2015-02-05 | Sequenta, Inc. | Monitoring immune responsiveness to cancer vaccination |
| EP2836611A4 (en) | 2012-04-13 | 2015-12-30 | Sequenta Inc | DETECTION AND QUANTIFICATION OF SAMPLE CONTAMINATION IN AN IMMUNOLOGICAL DIRECTORY ANALYSIS |
| WO2013158936A1 (en) | 2012-04-20 | 2013-10-24 | Sequenta, Inc | Monitoring immunoglobulin heavy chain evolution in b-cell acute lymphoblastic leukemia |
| US9150905B2 (en) | 2012-05-08 | 2015-10-06 | Adaptive Biotechnologies Corporation | Compositions and method for measuring and calibrating amplification bias in multiplexed PCR reactions |
| KR102702287B1 (ko) * | 2012-05-15 | 2024-09-04 | 브리스톨-마이어스 스큅 컴퍼니 | Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법 |
| WO2013181428A2 (en) | 2012-05-31 | 2013-12-05 | Sequenta, Inc. | Predicting relapse of chronic lymphocytic leukemia patients treated by allogeneic stem cell transplantation |
| US20130324422A1 (en) | 2012-06-04 | 2013-12-05 | Sequenta, Inc. | Detecting disease-correlated clonotypes from fixed samples |
| SG11201407888RA (en) | 2012-06-11 | 2014-12-30 | Sequenta Inc | Method of sequence determination using sequence tags |
| AU2013273987B2 (en) | 2012-06-15 | 2018-08-09 | Adaptive Biotechnologies Corporation | Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set |
| US20150247182A1 (en) | 2012-07-24 | 2015-09-03 | Adaptive Biotechnologies Corp. | Single cell analysis using sequence tags |
| JP2015524282A (ja) | 2012-08-10 | 2015-08-24 | シーケンタ インコーポレイテッド | 配列タグを用いた高感度突然変異検出 |
| CA2884246C (en) | 2012-09-24 | 2023-11-07 | Cb Biotechnologies, Inc. | Multiplex pyrosequencing using non-interfering noise-canceling polynucleotide identification tags |
| JP6449160B2 (ja) | 2012-10-01 | 2019-01-09 | アダプティブ バイオテクノロジーズ コーポレイション | 適応免疫受容体多様性およびクローン性特性決定による免疫能力評価関連出願の相互参照 |
| EP2909342A4 (en) | 2012-10-19 | 2016-06-22 | Adaptive Biotechnologies Corp | MONITORING OF LARGE B-CELL DIFFUSED LYMPHOMA FROM PERIPHERAL BLOOD SAMPLES |
| CA2888514A1 (en) | 2012-10-19 | 2014-04-24 | Sequenta, Inc. | Monitoring clonotypes of plasma cell proliferative disorders in peripheral blood |
| WO2014066184A1 (en) | 2012-10-22 | 2014-05-01 | Sequenta, Inc. | Monitoring mantle cell lymphoma clonotypes in peripheral blood after immunotransplant |
| ES2748204T3 (es) | 2013-02-22 | 2020-03-13 | Adaptive Biotechnologies Corp | Procedimiento para seleccionar clonotipos raros |
| US20140255944A1 (en) | 2013-03-08 | 2014-09-11 | Sequenta, Inc. | Monitoring treatment-resistant clones in lymphoid and myeloid neoplasms by relative levels of evolved clonotypes |
| US20140255929A1 (en) | 2013-03-11 | 2014-09-11 | Sequenta, Inc. | Mosaic tags for labeling templates in large-scale amplifications |
| US9708657B2 (en) | 2013-07-01 | 2017-07-18 | Adaptive Biotechnologies Corp. | Method for generating clonotype profiles using sequence tags |
| US20160186260A1 (en) | 2013-07-26 | 2016-06-30 | Sequenta, Llc | Cancer vaccination with antigen evolution |
| AU2014337063A1 (en) * | 2013-10-18 | 2016-05-19 | Adaptive Biotechnologies Corp. | Predicting patient responsiveness to immune checkpoint inhibitors |
| EP3092318A4 (en) | 2014-01-10 | 2017-08-16 | Adaptive Biotechnologies Corp. | Methods for defining and predicting immune response to allograft |
| US20150218656A1 (en) | 2014-02-03 | 2015-08-06 | Adaptive Biotechnologies Corp. | Methods for detection and diagnosis of a lymphoid malignancy using high throughput sequencing |
| US10066265B2 (en) | 2014-04-01 | 2018-09-04 | Adaptive Biotechnologies Corp. | Determining antigen-specific t-cells |
| EP3715455A1 (en) | 2014-10-29 | 2020-09-30 | Adaptive Biotechnologies Corp. | Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples |
| CA2968543C (en) | 2014-11-25 | 2024-04-02 | Adaptive Biotechnologies Corporation | Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing |
-
2013
- 2013-10-01 JP JP2015534819A patent/JP6449160B2/ja active Active
- 2013-10-01 EP EP17199432.0A patent/EP3330384B1/en active Active
- 2013-10-01 ES ES13779666.0T patent/ES2660027T3/es active Active
- 2013-10-01 EP EP19199181.9A patent/EP3640343A1/en active Pending
- 2013-10-01 AU AU2013327423A patent/AU2013327423B2/en active Active
- 2013-10-01 DK DK13779666.0T patent/DK2904111T3/da active
- 2013-10-01 CN CN201380062886.6A patent/CN105189779B/zh active Active
- 2013-10-01 CA CA2886647A patent/CA2886647A1/en not_active Abandoned
- 2013-10-01 WO PCT/US2013/062925 patent/WO2014055561A1/en not_active Ceased
- 2013-10-01 EP EP13779666.0A patent/EP2904111B1/en active Active
- 2013-10-01 ES ES17199432T patent/ES2749118T3/es active Active
- 2013-10-01 US US14/432,738 patent/US20160002731A1/en not_active Abandoned
-
2015
- 2015-04-01 IL IL238093A patent/IL238093B/en active IP Right Grant
-
2017
- 2017-06-29 US US15/637,871 patent/US10221461B2/en active Active
- 2017-09-08 AU AU2017225130A patent/AU2017225130B2/en active Active
-
2018
- 2018-05-11 US US15/977,258 patent/US11180813B2/en active Active
-
2021
- 2021-11-18 US US17/455,651 patent/US12104211B2/en active Active
-
2024
- 2024-09-27 US US18/899,708 patent/US20250101531A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12104211B2 (en) | 2024-10-01 |
| CA2886647A1 (en) | 2014-04-10 |
| AU2013327423A1 (en) | 2015-05-14 |
| EP3640343A1 (en) | 2020-04-22 |
| AU2013327423B2 (en) | 2017-06-22 |
| US20180030543A1 (en) | 2018-02-01 |
| WO2014055561A1 (en) | 2014-04-10 |
| IL238093A0 (en) | 2015-05-31 |
| US11180813B2 (en) | 2021-11-23 |
| AU2017225130B2 (en) | 2018-11-15 |
| US20250101531A1 (en) | 2025-03-27 |
| JP2015536642A (ja) | 2015-12-24 |
| EP3330384B1 (en) | 2019-09-25 |
| ES2660027T3 (es) | 2018-03-20 |
| US20180265931A1 (en) | 2018-09-20 |
| EP2904111A1 (en) | 2015-08-12 |
| US20160002731A1 (en) | 2016-01-07 |
| US10221461B2 (en) | 2019-03-05 |
| US20220298575A1 (en) | 2022-09-22 |
| ES2749118T3 (es) | 2020-03-19 |
| EP3330384A1 (en) | 2018-06-06 |
| IL238093B (en) | 2019-09-26 |
| CN105189779A (zh) | 2015-12-23 |
| CN105189779B (zh) | 2018-05-11 |
| JP6449160B2 (ja) | 2019-01-09 |
| AU2017225130A1 (en) | 2017-10-05 |
| EP2904111B1 (en) | 2017-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12104211B2 (en) | Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization | |
| US20150218656A1 (en) | Methods for detection and diagnosis of a lymphoid malignancy using high throughput sequencing | |
| Amisaki et al. | IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer | |
| US9824179B2 (en) | Diagnosis of lymphoid malignancies and minimal residual disease detection | |
| US20160340729A1 (en) | Methods for defining and predicting immune response to allograft | |
| Chand et al. | Botensilimab, an Fc-enhanced anti–CTLA-4 antibody, is effective against tumors poorly responsive to conventional immunotherapy | |
| US20240105283A1 (en) | Tumor phenotype prediction using genomic analyses indicative of digital-pathology metrics | |
| Thomas et al. | Altered interactions between circulating and tissue-resident CD8 T cells with the colonic mucosa define colitis associated with immune checkpoint inhibitors | |
| WO2020232148A1 (en) | Macrophage diversity in regenerative, fibrotic biomaterial environments | |
| HK40028024A (en) | Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization | |
| Morgan | Integrated, single-cell analysis of transcriptional phenotype and clonotypic identity | |
| Stewart | The Contribution of the Appendiceal Adaptive Immune Compartment During Inflammation | |
| Sutcliffe | Exploring the Influence of Treatment on CD4+ T-Cell Sub-Populations in Patients Receiving Biologic Drugs for Their Inflammatory Arthritis | |
| Sillo | Germline and somatic determinants of the immune contexture in colorectal cancer | |
| Corraliza Márquez | Immune mechanisms involved in inducing remission in Crohn’s disease patients undergoing hematopoietic stem cell transplant | |
| Raeburn | Characterization of TCRβ sequence diversity in colorectal carcinoma | |
| US20100291563A1 (en) | Assessing tissue rejection | |
| AU2011249583A1 (en) | Method of determining kidney transplantation tolerance |